Tag Archives: Neuralstem

Induction of immune tolerance by short-course immunosuppresion after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury.

Current clinical protocols use transient or continuous immunosuppression in patients receiving allogeneic neural precursor grafts for treatment of a variety of neurological diseases, including spinal trauma, stroke or ALS. At present there is no solid evidence, however, that would confirm … Continue reading

Posted in Chronic Spinal Cord Injury Research, Neuroscience Abstracts, Regenerative Medicine, Rehabilitation, Spinal Research, Stem Cell Research | Tagged | 1 Comment

Neuralstem flirting with stem cell noncompliance in Colorado via Right To Try Law?

I frequently check in to see what’s happening at the Paul Knoepfler Stem Cell blog. His post yesterday took me by complete surprise. Even though SCI isn’t part of the PTT Law, this will be an interesting situation to follow. … Continue reading

Posted in Regenerative Medicine | Tagged , ,

Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego (NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury)

Neuralstem, Inc. announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI Phase … Continue reading

Posted in Chronic Spinal Cord Injury Research, Spinal Research, Stem Cell Research | Tagged

Neuralstem: World Stem Cells & Regenerative Medicine Congress 2013

Richard Garr, President & CEO of Neuralstem gives his presentation on ‘Understanding the Practicalities of Using Innovative Therapies on Patients’ at the World Stem Cells & Regenerative Medicine Congress 2013.

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research, Uncategorized | Tagged ,

Neuralstem Receives FDA Approval for Chronic SCI Trial

ROCKVILLE, Md., Jan. 14, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, … Continue reading

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Unite 2 Fight Paralysis | Tagged , , , , , , , , ,